What the clinical trials showed The most widely discussed semaglutide data come from the SUSTAIN programme in type 2 diabetes and the STEP programme in obesity and overweight management
Its important to note that Retatrutide is still in clinical trials and not yet approved for public use
These studies provide valuable information on the options available after achieving weight loss goals
Rao SV, Kirsch B, Bhatt DL et al (2022) A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction
On the opposite, MCK1 deletion appeared to slightly enhance the methionine auxotrophy of CYS4 -OE cells (Figure 2C), suggesting that in the absence of Mck1p, Cys4p activity may be promoted